Skip to main content

Y-mAbs Therapeutics, Inc.

YMABDelisted Sep 16, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001722964

Y-mAbs Therapeutics, Inc. was delisted on Sep 16, 2025; its insiders filed their last Form 4 on Sep 19, 2025; 97 institutions reported holding it in 13F filings for Q2 2025, worth $125.9M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Y-mAbs Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Y-mAbs Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Y-mAbs Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Hamill LauraDirector0Sep 19, 20250
Gill David NDirector0Sep 18, 20250
Healy JamesDirector0IndirectSep 18, 20250
Pfreundschuh Peter P.EVP, CFO and Treasurer0Sep 18, 20250
LaRocca JohnSVP, General Counsel & Secry0Sep 18, 20250
Tyagi AshuDirector0Sep 18, 20250
Wedell-Wedellsborg JohanDirector, 10% Owner0IndirectSep 18, 20250
WG Biotech ApSDirector, 10% Owner0Sep 18, 20250
Gad ThomasCHIEF BUSINESS OFFICER0IndirectSep 18, 20250
Wilms JorisSVP & CHIEF OPERATING OFFICER0Sep 18, 20250
Rossi Michael JPRESIDENT & CEO0Sep 18, 20250
Gentilcore Douglas JSVP, Danyelza Bus. Unit Head–Sep 18, 20250
Lund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICER35,600Aug 30, 20240
Tagliaferri MaryDirector8,155Jun 13, 20240
Ber GerardDirector1,608Jun 11, 20240
Kruse BoEVP, CFO, SECRY & TREAS.210,877May 31, 20240
Rajah VigneshSVP & CHIEF MEDICAL OFFICER33,889Mar 7, 20240
Smith Susan LauraSVP & CHIEF COMMERCIAL OFFICER33,918Mar 7, 20240
Lisby SteenSVP & CHIEF SCIENTIFIC OFFICER35,600Jan 22, 20240
Moller-San Pedro Claus JuanDirector and CEO–Dec 16, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 11, 2025 (view filing)Mar 74 daysRossi Michael JPRESIDENT & CEOSSale−3.92K$5.20−$20.4K−2.8%137.1K after
Mar 11, 2025 (view filing)Mar 74 daysGad ThomasCHIEF BUSINESS OFFICERSSale−10.8K$5.23−$56.5K−5.1%202.7K after
Sep 17, 2024 (view filing)Sep 13-164 daysGad ThomasCHIEF BUSINESS OFFICERSSale−95.0K$13.31−$1.26M−58.4%67.7K after2 lots
Aug 30, 2024 (view filing)Aug 282 daysLund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICERSSale−50.0K$15.37−$768.5K−58.4%35.6K after
Aug 27, 2024 (view filing)Aug 261 dayWilms JorisSVP & CHIEF OPERATING OFFICERSSale−5.00K$14.69−$73.5K−14.0%30.6K after
Jun 11, 2024 (view filing)Jun 101 dayBer GerardDirectorSSale−722$12.00−$8.66K−31.0%1.61K after
Jun 11, 2024 (view filing)Jun 10-111 dayGad ThomasCHIEF BUSINESS OFFICERSSale−70.0K$12.02−$841.0K−30.1%162.7K after2 lots
May 31, 2024 (view filing)May 30-311 dayKruse BoEVP, CFO, SECRY & TREAS.SSale−60.0K$12.05−$723.1K−22.2%210.9K after2 lots
May 23, 2024 (view filing)May 21-232 daysGad ThomasCHIEF BUSINESS OFFICERSSale−32.4K$12.23−$395.6K−12.2%232.7K after2 lots
Mar 7, 2024 (view filing)Mar 52 daysRajah VigneshSVP & CHIEF MEDICAL OFFICERSSale−1.71K$16.53−$28.3K−4.8%33.9K after
Mar 7, 2024 (view filing)Mar 52 daysGad ThomasCHIEF BUSINESS OFFICERSSale−3.90K$16.44−$64.1K−2.4%158.7K after
Mar 7, 2024 (view filing)Mar 52 daysSmith Susan LauraSVP & CHIEF COMMERCIAL OFFICERSSale−1.68K$16.55−$27.8K−4.7%33.9K after
Dec 15, 2023 (view filing)Dec 13-152 daysGad ThomasChief Business OfficerSSale−150.0K$6.67−$1.00M−36.1%265.0K after3 lots
Dec 12, 2023 (view filing)Dec 111 dayWG Biotech ApSDirectorPPurchase+6.46K$6.85+$44.2K+0.1%4.56M afterDuplicate filing
Dec 12, 2023 (view filing)Dec 111 dayWedell-Wedellsborg JohanDirectorPPurchase+6.46K$6.85+$44.2K+0.1%4.56M after
Dec 11, 2023 (view filing)Dec 74 daysWG Biotech ApSDirectorPPurchase+6.18K$6.50+$40.2K+0.1%4.43M after
Dec 11, 2023 (view filing)Dec 8-113 daysWG Biotech ApSDirectorPPurchase+121.4K$7.01+$850.4K+2.7%4.55M after2 lots
Dec 11, 2023 (view filing)Dec 7-114 daysWedell-Wedellsborg JohanDirectorPPurchase+127.5K$6.98+$890.6K+2.9%4.55M after3 lots
Dec 1, 2023 (view filing)Nov 292 daysWG Biotech ApSDirectorPPurchase+51.8K$5.97+$309.5K+1.2%4.43M afterDuplicate filing
Dec 1, 2023 (view filing)Nov 292 daysWedell-Wedellsborg JohanDirectorPPurchase+51.8K$5.97+$309.5K+1.2%4.43M after
Nov 29, 2023 (view filing)Nov 27-282 daysWedell-Wedellsborg JohanDirectorPPurchase+93.2K$5.60+$521.4K+2.2%4.37M after2 lotsDuplicate filing
Nov 29, 2023 (view filing)Nov 27-282 daysWG Biotech ApSDirectorPPurchase+93.2K$5.60+$521.4K+2.2%4.37M after2 lots
Nov 22, 2023 (view filing)Nov 20-212 daysGad ThomasChief Business OfficerSSale−150.0K$5.31−$795.8K−26.5%415.0K after2 lots
May 17, 2023 (view filing)May 152 daysWedell-Wedellsborg JohanDirectorPPurchase+101.7K$9.65+$981.8K+2.4%4.28M afterDuplicate filing
May 17, 2023 (view filing)May 152 daysWG Biotech ApSDirector, Other: See remarksPPurchase+101.7K$9.65+$981.8K+2.4%4.28M after
Nov 16, 2022 (view filing)Nov 151 dayRajah VigneshSVP & CMOPPurchase+1.20K$4.92+$5.88K+38.9%4.27K after
Feb 23, 2022 (view filing)Feb 221 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$7.85−$31.4K−2.2%181.1K after
Feb 9, 2022 (view filing)Feb 7-92 daysGad ThomasSee remarksSSale−281.2K$7.19−$2.02M−33.2%565.0K after3 lots
Feb 7, 2022 (view filing)Feb 43 daysKruse BoEVP, CFO, Secretary & TreasSSale−4.00K$7.97−$31.9K−2.1%185.1K after
Feb 7, 2022 (view filing)Feb 3-44 daysGad ThomasSee remarksSSale−136.2K$7.75−$1.06M−13.9%846.2K after2 lots
Feb 3, 2022 (view filing)Feb 12 daysGad ThomasSee remarksSSale−8.00K$10.15−$81.2K−13.8%50.0K after
Jan 26, 2022 (view filing)Jan 242 daysGad ThomasSee remarksSSale−88.1K$10.63−$936.4K−8.2%982.4K after2 lots
Jan 25, 2022 (view filing)Jan 241 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$9.84−$39.4K−2.1%189.1K after
Jan 24, 2022 (view filing)Jan 20-214 daysGad ThomasSee remarksSSale−183.1K$11.11−$2.03M−14.6%1.07M after3 lots
Jan 20, 2022 (view filing)Jan 182 daysGad ThomasSee remarksSSale−8.00K$11.54−$92.3K−13.8%50.0K after
Jan 20, 2022 (view filing)Jan 18-192 daysGad ThomasSee remarksSSale−69.8K$10.89−$760.5K−5.3%1.25M after2 lots
Jan 5, 2022 (view filing)Jan 41 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$17.12−$68.5K−2.0%193.1K after
Dec 23, 2021 (view filing)Dec 221 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$16.36−$65.4K−2.0%197.1K after
Dec 8, 2021 (view filing)Dec 6-72 daysGad ThomasSee remarksSSale−54.0K$16.69−$901.0K−3.8%1.38M after3 lots
Dec 7, 2021 (view filing)Dec 61 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$16.35−$65.4K−2.0%201.1K after
Dec 1, 2021 (view filing)Nov 29-302 daysGad ThomasSee remarksSSale−47.6K$17.11−$814.5K−3.2%1.44M after5 lots
Nov 26, 2021 (view filing)Nov 233 daysGad ThomasSee remarksSSale−50.0K$17.06−$853.0K−50.0%50.0K after
Nov 23, 2021 (view filing)Nov 221 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$18.09−$72.4K−1.9%205.1K after
Nov 18, 2021 (view filing)Nov 162 daysGad ThomasSee remarksSSale−4.00K$19.33−$77.3K−0.3%1.48M after
Nov 5, 2021 (view filing)Nov 41 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$27.54−$110.2K−1.9%209.1K after
Nov 1, 2021 (view filing)Oct 293 daysGad ThomasSee remarksSSale−4.00K$24.82−$99.3K−0.3%1.49M after
Oct 26, 2021 (view filing)Oct 224 daysKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$25.94−$103.8K−1.8%213.1K after
Oct 19, 2021 (view filing)Oct 154 daysGad ThomasSee remarksSSale−4.00K$27.20−$108.8K−0.3%1.49M after
Oct 5, 2021 (view filing)Oct 41 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$28.78−$115.1K−1.8%217.1K after
Oct 4, 2021 (view filing)Sep 304 daysGad ThomasSee remarksSSale−4.00K$28.26−$113.0K−0.3%1.50M after